Navigation Links
ONCOTHYREON ANNOUNCES PRICING OF $14.9 MILLION PRIVATE PLACEMENT
Date:9/24/2010

SEATTLE, WA, Sept. 24 /PRNewswire-FirstCall/ - Oncothyreon Inc. (Nasdaq: ONTY), announced it has entered into a securities purchase agreement in connection with a private placement. Upon the closing of the private placement, Oncothyreon will receive gross proceeds of approximately $14.9 million resulting from the sale of approximately 4.24 million units at a purchase price of $3.50 per unit. The purchase price per unit represents approximately a 7.2% discount to the 30-day trailing volume-weighted average price of Oncothyreon's common stock through September 23, 2010. Each unit consists of one share of Oncothyreon's common stock and a warrant to purchase 0.75 of a share of common stock. The warrants have an exercise price of $4.20 per share and will be exercisable at any time on or after the six-month anniversary of the closing date and prior to the fifth anniversary of the earlier of the date on which the shares underlying the warrants may be freely sold pursuant to a resale registration statement or under Rule 144 promulgated under the Securities Act of 1933. The closing of the private placement is expected to take place on September 28, 2010 and is subject to the satisfaction of customary closing conditions. In connection with the closing, Oncothyreon will enter into a registration rights agreement with the purchasers of the securities issued in the private placement. Oncothyreon plans to use the proceeds from the private placement for general corporate purposes.

JMP Securities LLC acted as the lead placement agent and ROTH Capital Partners, LLC as the co-agent for the private placement transaction.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or
'/>"/>

SOURCE Oncothyreon Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. ONCOTHYREON APPOINTS JULIE M. EASTLAND AS CHIEF FINANCIAL OFFICER
2. Oncothyreon reports second quarter 2010 financial results
3. Oncothyreon announces second quarter 2010 financial results conference call
4. Oncothyreon announces presentations at upcoming investor conferences in June
5. Oncothyreon to present at the Rodman & Renshaw Annual Global Investment Conference
6. Oncothyreon reports full year and fourth quarter 2009 financial results
7. Oncothyreon reports first quarter 2010 financial results
8. Oncothyreon announces temporary suspension of Stimuvax clinical trials by Merck Serono
9. Oncothyreon consults with Division of Corporation Finance about accounting for 2008 License Agreement
10. Oncothyreons PX-866 PI-3 kinase inhibitor named among Top 10 most promising oncology products for partnering by Windhover
11. Oncothyreon reports third quarter 2009 financial results & provides product pipeline update
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/1/2014)... San Francisco, California (PRWEB) October 01, 2014 ... grant from the National Science Foundation to expand their ... approaches to build and modify DNA. The Small Business ... help commercialize the “j5” technology under exclusive license from ... the Joint BioEnergy Institute , an LBNL laboratory ...
(Date:10/1/2014)... , October 1, 2014 ... software invited to engage around the theme, ,Commercial Opportunities ...   Elsevier , a ... and services, will host a gathering of some of ... and trends impacting healthcare today and in the future. ...
(Date:9/30/2014)... This news release is available in German . ... at the Technische Universitt Mnchen (TUM) have demonstrated a ... Their experiments show that future computer chips could be ... transistors. As the main enabling technology of the semiconductor ... fundamental limits, the TUM researchers and collaborators at the ...
(Date:9/30/2014)... , Sept. 30, 2014 Report Details ... with highest potential revenues Do you want to ... gives you revenue predictions for those biological drugs ... therapies you find financial data, R&D trends, opportunities ... get sales forecasts to 2024 at overall world ...
Breaking Biology Technology:TeselaGen Receives $750k NSF SBIR Phase II Award 2TeselaGen Receives $750k NSF SBIR Phase II Award 3Elsevier Healthcare and Pharmaceutical Economics Conference 2014 To Convene Industry Leaders to Discuss Top Healthcare Business Issues 2Elsevier Healthcare and Pharmaceutical Economics Conference 2014 To Convene Industry Leaders to Discuss Top Healthcare Business Issues 3A new dimension for integrated circuits: 3-D nanomagnetic logic 2A new dimension for integrated circuits: 3-D nanomagnetic logic 3Biosimilars and Follow-On Biologics: World Industry and Market Prospects 2014-2024 2Biosimilars and Follow-On Biologics: World Industry and Market Prospects 2014-2024 3Biosimilars and Follow-On Biologics: World Industry and Market Prospects 2014-2024 4Biosimilars and Follow-On Biologics: World Industry and Market Prospects 2014-2024 5
... , M. Adams ... NJ, US, , ... DNA and sequencing template preparation needs. A combination of these kits with the Genesis ... high-throughput DNA preparation. , ...
... <P , ,>O. Rönn 1 , M. Landström 2 , A. Edman-Örlefors 1 ... 1 GE Healthcare, Uppsala, Sweden , ... Research, Uppsala, Sweden , , ... proteins at picogram levels, with linearity over 3.6 orders of magnitude. Two antigens ...
... , ... assay • LEADseeker • SPA Imaging Beads , ... biogenic amine that plays important pathophysiological roles in central and peripheral tissues. ... that characterize allergic responses (1).The function of histamine is mediated via four ...
Cached Biology Technology:Automation of TempliPhi and GenomiPhi DNA Amplification Kits on the Genesis Freedom Robotic Sample Processor 2Automation of TempliPhi and GenomiPhi DNA Amplification Kits on the Genesis Freedom Robotic Sample Processor 3Detection and quantitation of low-abundant proteins with ECL Plex fluorescent Western blotting 2Detection and quantitation of low-abundant proteins with ECL Plex fluorescent Western blotting 3Development of a histamine H1 receptor binding assay using the LEADseeker Multimodality Imaging System 2Development of a histamine H1 receptor binding assay using the LEADseeker Multimodality Imaging System 3Development of a histamine H1 receptor binding assay using the LEADseeker Multimodality Imaging System 4Development of a histamine H1 receptor binding assay using the LEADseeker Multimodality Imaging System 5
(Date:9/30/2014)... in Munich report that a new class of ... chemotherapeutic drugs. They have also pinpointed the relevant ... anti-tumor agents. , Researchers led by LMU,s ... the Technische Universitt Mnchen have identified a class ... in the fight against malignant tumors. The compound ...
(Date:9/30/2014)... available in German . ... response to risky situations such as exposure to predators. ... found in a long-term study on different populations of ... rate and ambient temperature. High metabolic rates and low ... these scenarios birds were more likely to approach potential ...
(Date:9/30/2014)... Ill. (September 30, 2014) People who suffer from ... do to control their asthma besides properly taking medications ... new article in the Annals of Allergy, Asthma ... College of Allergy, Asthma and Immunology (ACAAI), asthma sufferers ... their lifestyle. The woman described in the Annals article ...
Breaking Biology News(10 mins):Cancer therapy: Driving cancer cells to suicide 2Risky metabolism 2Asthma symptoms kicking up? Check your exposure to air pollution 2
... Researchers at the Tufts University School of Engineering ... first large area metamaterial structures patterned on implantable, ... July 21, 2010, in the journal Advanced ... development of a new class of metamaterial-inspired implantable ...
... 2010 How toxic, blue-green algae out-compete other organisms ... so doing proliferate dangerously in freshwater bodies -- has ... of Jerusalem. In general, the increasing occurrence ... is a matter of growing international concern due to ...
... Hematopoietic stem cells (HSCs) have two unique abilities that ... into any kind of blood cell, which enables them to ... these qualities to a distinct locale or niche within the ... and function of the niche-forming constituents have not been clearly ...
Cached Biology News:Implantable silk metamaterials could advance biomedicine, biosensing 2Implantable silk metamaterials could advance biomedicine, biosensing 3How algae 'enslavement' threatens freshwater bodies described by Hebrew University researcher 2Researchers find that one type of stem cell creates a niche for another type in bone marrow 2Researchers find that one type of stem cell creates a niche for another type in bone marrow 3
... BD BioCoat Collagen I 60 mm Culture ... Culture Dishes, tissue-culture treated polystyrene with a uniform ... Coating : Collagen I ,Surface ... 21.3 cm2 ,Dim nominal : ...
... new product number, created to easily match ... yet, please order under the old Sigma-Aldrich ... assistance. ID clarifier: tissue-culture treated ... 100 20 mm surface area 55 ...
BD BioCoat Gelatin 100 mm Culture Dishes, tissue-culture treated polystyrene with a uniform application of gelatin....
Mouse monoclonal antibody raised against a full length recombinant ATF3. NCBI Entrez Gene ID = ATF3...
Biology Products: